PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
StreetZero Signal 51
About PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a leading provider of high-quality, long-read sequencing platforms based in Menlo Park, CA. The company empowers life scientists with highly accurate long-read sequencing through its innovative instruments using Single Molecule, Real-Time (SMRTยฎ) Sequencing technology. This technology delivers a comprehensive view of genomes, transcriptomes, and epigenomes.
LATEST FUNDINGRule 144
$33K
Announced 2026-11-17
IN THE NEWS
- ๐ Pacific Biosciences Announces $900 Million Investment from SoftBank to Support Growth Initiatives - PacBio
- ๐ Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock - PacBio
- ๐ Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock - PacBio
- ๐ Pacific Biosciences signs stock sale deal for up to $100M | PACB 8-K Filing
- ๐ Pacific Biosciences of California, Inc. (NASDAQ:PACB) is favoured by institutional owners who hold 64% of the company
EMPLOYEESโ
FOUNDEDโ
HQMenlo Park, CA
Industry
Public Equity (NASDAQ)
Tags
BiotechGenomicsSequencingPublic
Investors
Key highlights
- Completed $900 million convertible notes investment from SoftBank subsidiary in 2021.
- Announced $150 million public offering of common stock in January 2023.
- Maintains at-the-market equity facility for up to $100 million via Allen & Company.
- NASDAQ-listed company with 64% institutional ownership.
- Focuses on SMRT Sequencing technology for comprehensive genomic analysis.
Ask StreetZero about PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account